Install
Zacks Small Cap Research coverage specifically looks to focus on small and micro-cap companies that are under followed or under valued by Wall Street.
- 38articles · 30d
- 3+ day agolatest article
- Aug 17, 2026earliest in window
- 0%with images
- 298avg words
- Economy, Business & Finance 33
- Finance & Business 25
- News 21
- Health & Wellness 10
- Medical 8
- Business & Industrial 6
- Industrial 5
- Health 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction
3+ day, 16+ hour ago (1108+ words) By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Preclinical Results Provide Insight into DA-1726 Mechanism of Waist Reduction On September 9, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the results of a preclinical study utilizing radioactively labeled…...
LEXX: Introducing DehydraTECH 3.0
5+ day, 18+ hour ago (868+ words) //s27.q4cdn.com/906368049/files/pictures/2026/09082026_LEXX_1.png LEXX: Introducing DehydraTECH 3.0 Lexaria Bioscience Corp. (NASDAQ: LEXX) announced absorption data from its 2026 Animal Study #2 (GLP-1-A26-2). The canine study examined amycretin and retatrutide bioavailability using oral delivery compared to reference formats. 18 different study arms were evaluated,…...
CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise
1+ week, 6+ day ago (166+ words) READ THE FULL CVKD RESEARCH REPORT Launches Strategic Partnering Process for Cardiac Acute Critical Care Franchise Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) has launched a structured strategic partnering process for its Cardiac Acute Critical Care Franchise that is centered on three…...
LABT: Advancing Toward Phase 2a Study of Nu-3 in Infected Diabetic Foot Ulcers
2+ week, 4+ day ago (758+ words) //s27.q4cdn.com/906368049/files/pictures/2026/08262026_LABT_1.png LABT: Advancing Toward Phase 2a Study of Nu-3 in Infected Diabetic Foot Ulcers Finalizing Preparations for Phase 2a Trial of Nu-3 in infected diabetic foot ulcers Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) is continuing final preparations for the upcoming Phase…...
AEMD: Oncology Study Advances; Cost-Efficient Preclinical Activities Regarding Other Diseases Continue
3+ week, 4+ day ago (212+ words) READ THE FULL AEMD RESEARCH REPORT Early observations from 1st two cohorts showed consistent improvements in immune function Aethlon Medical (NASDAQ: AEMD), a clinical-stage medical therapeutic company advancing its lead asset, the Hemopurifier, to treat cancer and life-threatening viral infections, reported…...